Eli Lilly and Company (NYSE:LLY) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, July 25th. Analysts expect the company to announce earnings of $1.05 per share for the quarter. Eli Lilly and has set its FY17 guidance at $4.05-4.15 EPS.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.96 by $0.02. The company had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.22 billion. Eli Lilly and had a net margin of 10.13% and a return on equity of 26.64%. Eli Lilly and’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.83 earnings per share. On average, analysts expect Eli Lilly and to post $4.12 EPS for the current fiscal year and $4.41 EPS for the next fiscal year.

Shares of Eli Lilly and Company (NYSE:LLY) opened at 83.64 on Tuesday. The stock has a market capitalization of $88.35 billion, a price-to-earnings ratio of 40.44 and a beta of 0.35. The stock’s 50 day moving average is $80.49 and its 200-day moving average is $79.95. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.49%. Eli Lilly and’s dividend payout ratio is presently 100.48%.

In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares in the company, valued at approximately $4,962,618.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Enrique A. Conterno sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, May 4th. The shares were sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the transaction, the senior vice president now owns 114,217 shares in the company, valued at approximately $9,452,598.92. The disclosure for this sale can be found here. In the last quarter, insiders have sold 474,733 shares of company stock valued at $39,634,487. 0.20% of the stock is currently owned by company insiders.

A number of research firms recently commented on LLY. UBS AG lifted their price target on shares of Eli Lilly and from $70.00 to $85.00 and gave the stock a “neutral” rating in a research note on Monday, March 20th. Deutsche Bank AG reaffirmed a “buy” rating and set a $91.00 price target (up from $90.00) on shares of Eli Lilly and in a research note on Monday. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research note on Monday. Cowen and Company lifted their price target on shares of Eli Lilly and from $85.00 to $95.00 and gave the stock an “outperform” rating in a research note on Monday, April 17th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $88.00 price target on shares of Eli Lilly and in a research note on Sunday, May 21st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $87.75.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and Company (LLY) to Release Quarterly Earnings on Tuesday” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/18/eli-lilly-and-company-lly-to-release-quarterly-earnings-on-tuesday.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.